Beta Bionics, Inc.

BBNX Healthcare Medical Devices

Beta Bionics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $100.3 million, up 53.9% from fiscal 2024.

Revenue
+30.3%
EPS
−58.6%
Free cash flow
−45.5%

Quarter to September 2026, against a year earlier

14.92 0.57 −3.68%
Market cap
$842.1M
P/E
0.0×
Fwd P/E
−8.2×
Dividend yield
—
F-score
5/9
Altman Z
16.89
Beneish M
−1.86
Dividend safety
n/a

Beta Bionics, Inc. (BBNX) P/E ratio

Alert me on P/E ratio

Beta Bionics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —

Quarterly newest first

Period P/E ratio Change
Sep 2026 0.0× —
Jun 2026 0.0× —
Mar 2026 0.0× —
Dec 2025 0.0× —
7 more quarters

Against its own ten years

Low 0.0× High 0.0×
Ten-year median 0.0×
Current reading's percentile 100

P/E ratio against peers

Company P/E ratio
CBLL CeriBell, Inc. compare n/m
PACB Pacific Biosciences of California, Inc. compare n/m
BBNX Beta Bionics, Inc. n/m
AHCO AdaptHealth Corp. compare n/m
QDEL QuidelOrtho Corporation compare n/m
KIDS OrthoPediatrics Corp. compare n/m
INMD InMode Ltd. compare 10.7×
BVS Bioventus Inc. compare 12.3×
VREX VAREX IMAGING compare 34.8×
Medical Devices industry median 25.6×
Healthcare sector median 25.2×
Market median 17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on BBNX